Interleukin-1-beta inhibitor - Aventis

Drug Profile

Interleukin-1-beta inhibitor - Aventis

Alternative Names: IL-1-beta antagonist - Aventis; IL-1-beta inhibitor - Aventis; Interleukin-1-beta antagonist - Aventis

Latest Information Update: 04 Jul 2002

Price : $50

At a glance

  • Originator Aventis
  • Class
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 11 Jul 2000 Preclinical development for Rheumatoid arthritis (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top